Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC ...Middle East

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 percent progression-free survival rate at 9-months signals...

Read More Details
Finally We wish PressBee provided you with enough information of ( Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC )

Also on site :

• 205 Funny Dares That Will Embarrass Your Whole Crew
• I Tried Pvolve—Here's My Honest Review
• Firefighters save baby after he turns purple; “The worst night of our lives”